Stockreport

Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF Named REVEAL-1 and REVEAL-2, the trials aim to assess the efficacy and safety of the subcutaneous doses of VRDN-003 in people with both active and chronic TED, respecti [Read more]